文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

危重型COVID-19患者个体化糖皮质激素治疗的候选变量:CIBERESUCICOVID研究

Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.
PubMed 文献 · Intensive Care Med · 2022-06-21
一句话结论在55个西班牙ICU的4226例COVID-19患者中,糖皮质激素降低90天死亡率(HR 0.77),但早期使用(症状出现<7天)与死亡率升高相关(HR 1.32)。

该多中心观察性队列纳入2020年2月至2021年10月55个西班牙ICU连续收治的4226例COVID-19患者,其中3592例(85%)住院期间接受全身糖皮质激素。倾向评分校正多变量分析显示,糖皮质激素对总体人群90天死亡率有保护作用(HR 0.77 [0.65-0.92],p=0.003),院内死亡率SHR 0.70 [0.58-0.84],p<0.001。年龄(交互p=0.001)、SOFA评分(交互p=0.014)和机械通气(交互p=0.001)存在显著效应修饰,≥60岁、基线病情更重及入ICU时接受有创机械通气的患者获益。早期给药(症状出现<7天)与90天死亡率升高相关(HR 1.32 [1.14-1.53],p<0.001),长疗程(≥10天)与死亡率降低相关(HR 0.71 [0.61-0.82],p<0.001),剂量无显著影响。糖皮质激素使用与院内细菌性肺炎和高血糖风险增加相关。

要点

  • 总体人群中糖皮质激素降低90天死亡率(HR 0.77 [0.65-0.92],p=0.003)和院内死亡率(SHR 0.70 [0.58-0.84],p<0.001)。
  • 年龄≥60岁、基线病情更重、入ICU时接受有创机械通气的患者90天死亡率获益更明显。
  • 早期给药(症状出现<7天)与90天死亡率升高相关(HR 1.32 [1.14-1.53],p<0.001)。
  • 长疗程(≥10天)与90天死亡率降低相关(HR 0.71 [0.61-0.82],p<0.001),高剂量(≥12 mg/天地塞米松等效剂量)未见显著效应。
  • 糖皮质激素使用与院内细菌性肺炎和高血糖风险增加相关。

适用人群与场景

  • 55个西班牙ICU连续收治的COVID-19患者,2020年2月至2021年10月纳入,共4226例。

处置流程与药物剂量

  • 糖皮质激素的使用可根据年龄、病情严重程度、基线炎症和有创机械通气进行个体化(作者认为可能)。
  • 早期给药(症状出现<7天)可能有害(作者认为)。

研究设计与关键结果

  • 多中心观察性队列研究,纳入55个西班牙ICU连续收治的4226例COVID-19患者;3592例(85%)住院期间接受全身糖皮质激素。
  • 倾向评分校正多变量分析:糖皮质激素对总体人群90天死亡率有保护作用(HR 0.77 [0.65-0.92],p=0.003),院内死亡率SHR 0.70 [0.58-0.84],p<0.001。
  • 年龄(交互p=0.001)、SOFA评分(交互p=0.014)和机械通气(交互p=0.001)存在显著效应修饰。
  • 糖皮质激素对90天死亡率的有益效应见于多个亚组:年龄≥60岁、基线病情更重、入ICU时接受有创机械通气的患者。
  • 早期给药(症状出现<7天)与总体人群90天死亡率升高相关(HR 1.32 [1.14-1.53],p<0.001)。
  • 长疗程(≥10天)与总体人群90天死亡率降低相关(HR 0.71 [0.61-0.82],p<0.001)。
  • 糖皮质激素剂量(≥12 mg/天地塞米松等效剂量)未见显著效应。
  • 糖皮质激素使用与院内细菌性肺炎和高血糖风险增加相关。

证据类型、等级与局限

  • 证据类型:多中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对ICU收治的COVID-19患者,糖皮质激素的使用可基于年龄、病情严重程度、基线炎症和有创机械通气进行个体化(作者认为可能)。
  • 自症状出现早期给药可能有害(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Although there is evidence supporting the benefits of corticosteroids in patients affected with severe coronavirus disease 2019 (COVID-19), there is little information related to their potential benefits or harm in some subgroups of patients admitted to the intensive care unit (ICU) with COVID-19. We aim to investigate to find candidate variables to guide personalized treatment with steroids in critically ill patients with COVID-19.

METHODS: Multicentre, observational cohort study including consecutive COVID-19 patients admitted to 55 Spanish ICUs. The primary outcome was 90-day mortality. Subsequent analyses in clinically relevant subgroups by age, ICU baseline illness severity, organ damage, laboratory findings and mechanical ventilation were performed. High doses of corticosteroids (≥ 12 mg/day equivalent dexamethasone dose), early administration of corticosteroid treatment (< 7 days since symptom onset) and long term of corticosteroids (≥ 10 days) were also investigated.

RESULTS: Between February 2020 and October 2021, 4226 patients were included. Of these, 3592 (85%) patients had received systemic corticosteroids during hospitalisation. In the propensity-adjusted multivariable analysis, the use of corticosteroids was protective for 90-day mortality in the overall population (HR 0.77 [0.65-0.92], p = 0.003) and in-hospital mortality (SHR 0.70 [0.58-0.84], p < 0.001). Significant effect modification was found after adjustment for covariates using propensity score for age (p = 0.001 interaction term), Sequential Organ Failure Assessment (SOFA) score (p = 0.014 interaction term), and mechanical ventilation (p = 0.001 interaction term). We observed a beneficial effect of corticosteroids on 90-day mortality in various patient subgroups, including those patients aged ≥ 60 years; those with higher baseline severity; and those receiving invasive mechanical ventilation at ICU admission. Early administration was associated with a higher risk of 90-day mortality in the overall population (HR 1.32 [1.14-1.53], p < 0.001). Long-term use was associated with a lower risk of 90-day mortality in the overall population (HR 0.71 [0.61-0.82], p < 0.001). No effect was found regarding the dosage of corticosteroids. Moreover, the use of corticosteroids was associated with an increased risk of nosocomial bacterial pneumonia and hyperglycaemia.

CONCLUSION: Corticosteroid in ICU-admitted patients with COVID-19 may be administered based on age, severity, baseline inflammation, and invasive mechanical ventilation. Early administration since symptom onset may prove harmful.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Torres A, Motos A, Cillóniz C, et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022. PMID: 35727348. doi:10.1007/s00134-022-06726-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。